線維嚢胞性乳房診断・治療市場、2030年までの予測：タイプ別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の線維嚢胞性乳房診断・治療市場は予測期間中にCAGR 9.9％で成長する見込みです。

乳房組織がしこりとなり、敏感で、時には痛みを伴う一般的な良性乳房疾患である線維嚢胞性乳房疾患に対する医療業界の対応は、線維嚢胞性乳房診断・治療市場に受け入れられています。非がん性の乳房のしこりの増大と関連する不快感は、一般的な病気である線維嚢胞性乳房の症状です。マンモグラフィ、超音波検査、時には生検が乳がんの診断手順の一部として用いられます。治療の目的は症状のコントロールであり、食事の調整、痛みに対する薬物療法、サポートブラジャーなどが行われます。

米国がん協会の評価によると、2018年だけで約26万6,120人の新たな乳がん症例が確認される可能性があり、約4万920人の女性が乳がんが原因で死亡する可能性があります。

女性の線維嚢胞性乳房の増加

市場成長を上昇させる要因は、女性人口のかなりの部分が罹患していると考えられている女性の線維嚢胞性乳房の高い発生率であり、診断リソースや治療に対する大きな需要を生み出し、医療専門家、製薬会社、医療機器メーカーの注目を集めています。さらに、この業界における新しい診断法や治療法の発明と採用は、個人と政府の両方による医療支出の増加によって支えられています。

高コスト

新しい診断法や治療法は患者のケアを改善する可能性を秘めているが、高額な費用がかかることが多く、より多くの人々が容易に利用できるものではないです。その結果、経済的に余裕のない人々や保険が十分に適用されない人々にとって、早期かつ効率的な診断や治療へのハードルとなる可能性があります。しかし、これは医療における不公平や不平等をもたらす可能性があります。特に農村部や過疎地では、専門医療施設や有能な人材が地理的に偏在しているため、アクセシビリティがさらに制約されることもあります。

技術開発

3Dマンモグラフィや高解像度超音波検査などの医療画像技術の発展により、線維嚢胞性乳房の診断精度は向上しています。デジタルヘルスツールや生検法の進歩も診断能力を向上させています。さらに、医療技術の発展により、線維嚢胞性乳房疾患の発見、追跡、治療の方法が激変しています。デジタルマンモグラフィや3D断層撮影のような最新の画像技術は、精度の向上と早期発見を可能にし、偽陽性や不必要な手術を最小限に抑えます。技術の進歩により、より低侵襲な生検方法で正確な組織採取が可能になり、患者の苦痛が軽減されました。

標的療法は限られている

技術の進歩にもかかわらず、線維嚢胞性乳房疾患に対する正確で焦点を絞った治療法は不足しています。根本的な原因に焦点を当てるのではなく、治療法は主に症状を管理するものです。病気の原因となっている分子的または遺伝的要素に特異的に取り組むことを目的とした標的治療薬の利用可能性は、わずかに制限されています。しかし、線維嚢胞性乳房疾患に対する正確で効率的な標的治療法の開発が困難なのは、この疾患の正確な病因が十分に理解されていないためと考えられます。

COVID-19の影響

COVID-19患者のためのスペースを確保するために、パンデミックのピーク時に延期または中止しなければならなかった緊急性のない医療処置やスクリーニングの中に、定期的なマンモグラムや乳房検査があっています。場合によっては、このような検診の遅れが、線維嚢胞性乳房のタイムリーな発見と診断を妨げた可能性があります。パンデミックの影響を受けたのは、いくつかの専門分野にわたる臨床試験と現在の調査でした。線維嚢胞性乳房の新規診断技術や治療法を検討する研究は、この遅れによって妨げられた可能性があります。

予測期間中、乳房生検分野が最大となる見込み

予測期間中、乳房生検分野が最大のシェアを占める。乳房生検は、線維嚢胞性変化の存在を確認し、悪性腫瘍と区別する信頼できる方法を提供するため、意識の高まりと早期発見の重視の結果、より一般的になってきています。さらに、線維嚢胞性乳房疾患の正確な診断と悪性の可能性のある増殖の除去は、生検手技に大きく依存しています。このパートでは、病理学的分析に必要な組織サンプルを採取するために使用できる、真空支援法、コアニードル法、細針吸引法などの多数の生検法を取り上げます。

予測期間中にCAGRが最も高くなると予想されるのは病院分野です。

診断と治療のための一次医療施設は、最先端の医療技術と経験を備えており、線維嚢胞性乳房の問題を完全に管理するための主要施設となっているため、病院カテゴリーは予測期間を通じて最も高いCAGRを有すると予想されます。さらに、患者の利便性と有効性のために、乳房の臨床検査から最先端の画像診断や生検治療に至るまで、さまざまな診断サービスを一つ屋根の下で提供することが多く、医療施設は複雑な症例の紹介拠点として機能することが多く、最先端の診断手順や手術などの専門家による治療を必要とする患者を惹きつけています。

最大のシェアを持つ地域：

アジア太平洋が最大のシェアを占めているのは、同地域の医療インフラが改善され、経済発展が進んでいるため、最先端の医療技術や治療法を手に入れやすく、利用しやすくなっているためです。さらに、アジア太平洋の積極的な研究開発努力の結果、革新的な診断・治療法も開発されており、通常は海外の医療機関と協力しています。

CAGRが最も高い地域：

アジア太平洋は、特にインドや中国のような膨大で多様な人口を抱え、潜在的な患者数が多いため、予測期間中に線維嚢胞性乳房診断・治療に対する需要が増加すると予想されます。さらに、乳房の健康と早期発見に対する意識の高まりが、教育プログラムや医療へのアクセスの簡便化によって拍車をかけているためです。これらの要因によって、より多くの女性が医師の診察を受け、乳房の検査やテストを受けるようになっています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場参入企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データ鉱業
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• イントロダクション
• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の線維嚢胞性乳房診断・治療市場：タイプ別

• イントロダクション
• 乳房生検
• 非ステロイド性抗炎症薬
• アセトアミノフェン
• 経口避妊薬
• その他のタイプ

第6章 世界の線維嚢胞性乳房診断・治療市場：エンドユーザー別

• イントロダクション
• 診断センター
• 病院
• 研究機関
• 専門クリニックとリハビリセンター
• その他のエンドユーザー

第7章 世界の線維嚢胞性乳房診断・治療市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東およびアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東およびアフリカ

第8章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第9章 企業プロファイル

• Argon Medical Devices
• Boston Scientific
• CareFusion Corporation
• Cook Medical, INRAD, Inc
• Devicor Medical Products Inc
• Allergan plc
• Bayer AG
• Teva Pharmaceutical Industries Ltd
• Merck & Co., Inc
• Gallini Medical Devices
• Pfizer Inc

List of Tables

• Table 1 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
• Table 4 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
• Table 5 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
• Table 6 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
• Table 7 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 8 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 9 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 10 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 11 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 12 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
• Table 13 Global Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 14 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 15 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 16 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
• Table 17 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
• Table 18 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
• Table 19 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
• Table 20 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 21 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 22 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 23 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 24 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 25 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
• Table 26 North America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 27 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 28 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 29 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
• Table 30 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
• Table 31 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
• Table 32 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
• Table 33 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 34 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 35 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 36 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 37 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 38 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
• Table 39 Europe Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 40 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 41 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 42 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
• Table 43 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
• Table 44 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
• Table 45 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
• Table 46 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 47 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 48 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 49 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 50 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 51 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
• Table 52 Asia Pacific Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 53 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 54 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 55 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
• Table 56 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
• Table 57 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
• Table 58 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
• Table 59 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 60 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 61 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 62 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 63 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 64 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
• Table 65 South America Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 66 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 67 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 68 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Breast Biopsy (2021-2030) ($MN)
• Table 69 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Nonsteroidal Anti Inflammatory Drugs (2021-2030) ($MN)
• Table 70 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Acetaminophen (2021-2030) ($MN)
• Table 71 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Oral Contraceptives (2021-2030) ($MN)
• Table 72 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 73 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 74 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 75 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 76 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 77 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Specialty Clinics and Rehab Centers (2021-2030) ($MN)
• Table 78 Middle East & Africa Fibrocystic Breasts Diagnostics and Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Fibrocystic Breasts Diagnostics and Treatment Market is expected to grow at a CAGR of 9.9% during the forecast period. The healthcare industry's response to fibrocystic breast disease, a common benign breast disorder in which the breast tissue becomes lumpy, sensitive, and sometimes painful, is embraced by the fibrocystic breasts diagnostics and treatment market. The growth of noncancerous breast lumps and related discomfort are symptoms of fibrocystic breasts, a common illness. Mammograms, ultrasounds, and occasionally biopsies are used as part of diagnostic procedures for breast cancer. The aim of treatment is symptom control, which may entail dietary adjustments, medications for pain, and supportive bras.

According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.

Market Dynamics:

Driver:

Rise of fibrocystic breasts in women

The factors that rise the market growth are high incidence of fibrocystic breasts in women, which is thought to affect a significant portion of the female population, generates significant demand for diagnostic resources and treatments, which attracts the attention of healthcare professionals, pharmaceutical firms, and manufacturers of medical equipment. Additionally, the invention and adoption of new diagnostic and treatment options in this industry are supported by rising healthcare spending by both individuals and governments.

Restraint:

High cost

While new diagnostic and therapeutic options have the potential to improve patient care, they frequently have a high cost, making them less readily available to a larger population. As a result, there may be hurdles to early and efficient diagnosis and treatment for people with limited financial resources or inadequate insurance coverage. However, this can result in inequities and inequalities in healthcare. Accessibility may also be further constrained by the uneven geographic distribution of specialized healthcare facilities and competent individuals, particularly in rural or underdeveloped areas.

Opportunity:

Technological developments

The accuracy of fibrocystic breast diagnoses has increased due to developments in medical imaging technology, including 3D mammography and high-resolution ultrasounds. Digital health tools and advancements in biopsy methods also improve diagnostic capabilities. Moreover, the way fibrocystic breast disease is detected, tracked, and treated has undergone a radical change because of developments in medical technology. Modern imaging technologies like digital mammography and 3D tomo synthesis offer improved precision and early detection, minimizing false positives and unnecessary operations. Technology has made it possible to do accurate tissue sampling with less invasive biopsy methods, reducing patient suffering.

Threat:

Targeted therapies are limited

There is a lack of accurate, focused therapy for fibrocystic breast disease despite advances in technology. Rather than focusing on the root causes, treatments mostly manage symptoms. The availability of targeted medicines, which are intended to specifically tackle the molecular or genetic components causing the illness, is slightly restricted. However, the difficulty in developing accurate and efficient targeted treatments for fibrocystic breast disease can be due to the absence of a thorough understanding of the precise etiology of the condition.

COVID-19 Impact:

Routine mammograms and breast examinations were among the non-urgent medical procedures and screenings that had to be delayed or canceled during the peak of the pandemic in order to make space for COVID-19 patients. In certain instances, this delay in screenings may have hampered the timely identification and diagnosis of fibrocystic breasts. Clinical trials and current research across several medical specialties were affected by the pandemic. Studies looking at novel diagnostic techniques or therapy options for fibrocystic breasts may have been hindered by this delay.

The breast biopsy segment is expected to be the largest during the forecast period

Breast Biopsy segment dominated the largest share over the forecast period. Breast biopsies are becoming more popular as a result of increased awareness and emphasis on early detection, as they provide a reliable way to confirm the presence of fibrocystic alterations and distinguish them from malignancies. Furthermore, the precise diagnosis of fibrocystic breast disease and the elimination of potentially malignant growths depend heavily on biopsy procedures. This part covers numerous biopsy methods that can be used to get the required tissue samples for pathological analysis, including vacuum-assisted, core needle, and fine needle aspiration.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital category is anticipated to have the highest CAGR throughout the projected period as primary healthcare facilities for diagnosis and treatment are equipped with cutting-edge medical technologies and experience, making them the go-to facilities for entirely managing fibrocystic breast problems. Moreover, for patients' convenience and effectiveness, they frequently provide a variety of diagnostic services under one roof, ranging from clinical breast exams to cutting-edge imaging and biopsy treatments, medical facilities frequently act as referral hubs for complicated cases, attracting patients in need of specialist care such as cutting-edge diagnostic procedures and operations.

Region with largest share:

The Asia Pacific region holds the largest share as a result of the region's improved healthcare infrastructure and growing economic development, which have increased the affordability and accessibility of cutting-edge medical technologies and treatments, making it simpler for patients to access cutting-edge diagnostic and treatment options. Additionally, innovative diagnosis and treatment methods have also been developed as a result of the Asia-Pacific region's active research and development efforts, usually in cooperation with foreign healthcare organizations.

Region with highest CAGR:

Due to the region's huge and varied population, particularly in countries like India and China, which contribute to a substantial number of potential patients, the Asia-Pacific region is expected to have an increase in demand for fibrocystic breast disease diagnostics and treatments over the projected period. Further, due to the growing awareness of breast health and early detection that has been spurred by education programs and simpler access to healthcare. These factors urge more women to seek medical attention and undergo breast exams and tests.

Key players in the market

Some of the key players in Fibrocystic Breasts Diagnostics and Treatment market include: Argon Medical Devices, Boston Scientific, CareFusion Corporation, Cook Medical, INRAD, Inc, Devicor Medical Products Inc, Allergan plc, Bayer AG, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc, Gallini Medical Devices and Pfizer Inc.

Key Developments:

In September 2023, Boston Scientific to buy chronic back pain therapy maker Relievant. Medical devices maker Boston Scientific (BSX.N) would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million, gaining access to an FDA-cleared therapy for chronic pain.

In March 2023, Argon Medical introduces Traveler Portal Vein Access Series. TRAVELER has been designed to improve the visualisation and durability of components, helping to address some of the common challenges faced during Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.

Types Covered:

• Breast Biopsy
• Nonsteroidal Anti Inflammatory Drugs
• Acetaminophen
• Oral Contraceptives
• Other Types

End Users Covered:

• Diagnostic Centers
• Hospitals
• Research Institutes
• Specialty Clinics and Rehab Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Fibrocystic Breasts Diagnostics and Treatment Market, By Type

• 5.1 Introduction
• 5.2 Breast Biopsy
• 5.3 Nonsteroidal Anti Inflammatory Drugs
• 5.4 Acetaminophen
• 5.5 Oral Contraceptives
• 5.6 Other Types

6 Global Fibrocystic Breasts Diagnostics and Treatment Market, By End User

• 6.1 Introduction
• 6.2 Diagnostic Centers
• 6.3 Hospitals
• 6.4 Research Institutes
• 6.5 Specialty Clinics and Rehab Centers
• 6.6 Other End Users

7 Global Fibrocystic Breasts Diagnostics and Treatment Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Argon Medical Devices
• 9.2 Boston Scientific
• 9.3 CareFusion Corporation
• 9.4 Cook Medical, INRAD, Inc
• 9.5 Devicor Medical Products Inc
• 9.6 Allergan plc
• 9.7 Bayer AG
• 9.8 Teva Pharmaceutical Industries Ltd
• 9.9 Merck & Co., Inc
• 9.10 Gallini Medical Devices
• 9.11 Pfizer Inc